Enlivex Therapeutics Ltd. Ordinary Shares - ENLV STOCK NEWS

Enlivex Therapeutics (Nasdaq: ENLV) announced its participation in the Reuters Events' Cell & Gene Therapy USA 2021 event, taking place virtually on September 28-29, 2021. Enlivex will present on September 29 at 11:30 a.m. EDT, discussing Allocetra's large-scale manufacturing process. Allocetra^TM is an innovative cell therapy aimed at reprogramming macrophages, critical in addressing severe diseases like solid cancers and COVID-19. The event will feature various industry leaders sharing insights on gene therapies.

Enlivex Therapeutics (Nasdaq: ENLV) has initiated a Phase IIb clinical trial to evaluate Allocetra^TM in patients with severe COVID-19 experiencing acute respiratory distress syndrome (ARDS). The trial aims to recruit up to 152 patients across Israel and Europe, with the primary endpoints being ventilation-free survival and recovery. Enlivex anticipates top-line results by Q2 2022. Previous trials showed a 0% mortality rate among 21 patients treated with Allocetra^TM, with 90.5% recovering within an average of 5.6 days. This trial represents a crucial step toward addressing severe COVID-19 cases.

Enlivex Therapeutics (Nasdaq: ENLV) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company focuses on macrophage reprogramming immunotherapy aimed at treating sepsis, COVID-19, and solid tumors. An on-demand presentation will be accessible starting 7:00 AM Eastern Time on September 13, 2021, through the provided link. Enlivex is advancing Allocetra™, a novel therapy designed to restore macrophage homeostasis, crucial for immune system balance.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has received authorization from the Israeli Ministry of Health to initiate a Phase IIb clinical trial of Allocetra^TM for severe COVID-19 patients with ARDS. The trial will enroll up to 152 patients across Israel and Europe, focusing on safety and efficacy alongside standard treatment. Previous trials showed Allocetra^TM achieved a 0% mortality rate and 90.5% recovery in severe cases within 28 days. The Phase IIb trial aims to evaluate ventilation-free survival and long-COVID symptoms.

Enlivex Therapeutics (ENLV) announced its Q2 2021 financial results and key clinical updates. The ongoing Phase IIb trial for Allocetra^TM in sepsis is anticipated to report top-line results in Q2 2022, with 120-160 patients expected in the study. A Phase IIb trial for Allocetra^TM in severe COVID-19 patients is set to start in Q3 2021. Enlivex also plans a Phase Ib trial to evaluate Allocetra^TM combined with chemotherapy for solid tumors. Financially, the company posted a net loss of $3.108 million, with cash and marketable securities of $90.6 million to fund operations through 2023.

Enlivex Therapeutics has announced the appointment of Tzvi Palash as Project Lead for the construction of its new cGMP Allocetra^TM manufacturing plant. With over 35 years of experience, including roles at Gamida Cell and Protalix Biotherapeutics, Palash is expected to enhance manufacturing capacity for upcoming clinical trials and potential commercialization. Allocetra^TM aims to reprogram macrophages, addressing critical health needs in conditions like sepsis and COVID-19, aligning with Enlivex’s goal of leading in cell therapies.

Enlivex Therapeutics (Nasdaq: ENLV) announced that its CEO, Dr. Oren Hershkovitz, will participate in the Improvate Life-Saving Technologies International Conference 2021 on July 22, 2021. Dr. Hershkovitz's interview, scheduled for 5:15 AM EDT, will focus on the company's Allocetra^TM macrophage reprogramming cell therapy platform, aimed at addressing life-threatening unmet medical needs. Attendees can access the live broadcast by registering on the conference's website.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation in the ARDS Drug Development Summit on July 15, 2021. The Company will present Allocetra^TM, a promising therapy for acute respiratory distress syndrome (ARDS), a condition with limited effective treatments. The inaugural summit aims to address drug development challenges for both COVID-19 and non-COVID-19 related ARDS. Allocetra^TM is designed to reprogram macrophages to restore immune balance, potentially serving life-threatening conditions.

Enlivex Therapeutics has announced the initiation of design and construction for a new cGMP manufacturing plant in Israel, aimed at expanding production capacity for its immunotherapy product Allocetra. This facility, initially planned to be 17,000 square feet with potential expansion to 21,500 square feet, will support ongoing and future clinical trials, along with initial commercial production upon regulatory approvals. CEO Oren Hershkovitz emphasized that this expansion is crucial for advancing clinical readiness for sepsis and COVID-19 treatments.